A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment. - Wikidata - wikimedia - TriplyDB

A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment.

A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment.

http://www.wikidata.org/entity/Q30421675

about

Normal and neoplastic urothelial stem cells: getting to the root of the problem Bladder cancer in 2011: the dawn of personalized medicine Multimodal management of muscle-invasive bladder cancer Translation initiation factor eIF3b expression in human cancer and its role in tumor growth and lung colonization Transcriptional signatures of Ral GTPase are associated with aggressive clinicopathologic characteristics in human cancer.A 20 gene model for predicting nodal involvement in bladder cancer patients with muscle invasive tumors.High expression of GEM and EDNRA is associated with metastasis and poor outcome in patients with advanced bladder cancer.Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum.Current therapeutic strategies for invasive and metastatic bladder cancer.A framework to select clinically relevant cancer cell lines for investigation by establishing their molecular similarity with primary human cancers Biomarkers for prognosis and treatment selection in advanced bladder cancer patients.An online tool for evaluating diagnostic and prognostic gene expression biomarkers in bladder cancer Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma Three differentiation states risk-stratify bladder cancer into distinct subtypes GON4L Drives Cancer Growth through a YY1-Androgen Receptor-CD24 Axis.Personalized medicine in breast cancer: a systematic review.A reported 20-gene expression signature to predict lymph node-positive disease at radical cystectomy for muscle-invasive bladder cancer is clinically not applicable.Drug Selection in the Genomic Age: Application of the Coexpression Extrapolation Principle for Drug Repositioning in Cancer Therapy.Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer.Multimodal therapies for muscle-invasive urothelial carcinoma of the bladder Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response.Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology.p63 expression correlates with sensitivity to the Eg5 inhibitor ZD4877 in bladder cancer cells.MicroRNA Expression Profile Identifies High Grade, Non-Muscle-Invasive Bladder Tumors at Elevated Risk to Progress to an Invasive Phenotype Serum total hCGβ level is an independent prognostic factor in transitional cell carcinoma of the urothelial tract.Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11.Molecular signatures that predict nodal metastasis in bladder cancer: does the primary tumor tell tales?When urothelial differentiation pathways go wrong: implications for bladder cancer development and progression.Urothelial carcinoma of the bladder: definition, treatment and future efforts.Clinical opportunities and challenges in targeting tumour dormancy.Selective organ preservation for the treatment of muscle-invasive transitional cell carcinoma of the bladder: a review of current and future perspectives.Prognostic and predictive miRNA biomarkers in bladder, kidney and prostate cancer: Where do we stand in biomarker development?Recent progress with next-generation biomarkers in muscle-invasive bladder cancer.Words of wisdom. Re: Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status.Clinical and therapeutic factors associated with adverse pathological outcomes in clinically node-negative patients treated with neoadjuvant cisplatin-based chemotherapy and radical cystectomy.Copy number gains at chr3p25 and chr11p11 are associated with lymph node involvement and survival in muscle-invasive bladder tumors.Predicting the biological behavior of non-muscle-invasive bladder cancer: from histology to molecular taxonomy.Extranodal extension of nodal metastasis is the main prognostic moderator in squamous cell carcinoma of the esophagus after neoadjuvant chemoradiotherapy.The Rho GTPase signalling pathway in urothelial carcinoma.Bladder cancer: bladder preservation--learning what we don't know.

P2860

Q26825948-C5682420-DC9E-427C-B139-5624E871D9DB Q26998718-127573BE-94D7-4BEC-B58A-3450A5FC7AA6 Q27011624-B8ACE834-E5DE-4EE8-9E1B-F09D2E353158 Q30416020-AA2A3CEF-2827-47C2-84C2-992AF7EE9BB2 Q30416201-AE6C9D72-F517-4499-B245-DCADA465444E Q30485127-C852DB90-AF7B-47CC-888B-57ACD2B79151 Q34184763-5FD72786-F5BA-4A41-B20D-46A0EF8F9D7C Q34670535-1CB8604A-A2B3-41BF-837F-EDBBD6F474BB Q35128721-97F83804-9C97-4F99-B41E-112EBEDAFB6A Q35624169-1941A1F7-7953-439E-823A-B04301F95109 Q35671292-BD0215FE-9A1B-49EF-8435-7078D7740E35 Q35678922-6F663B23-9599-481A-8E9F-5ABC289CD537 Q35731224-9498BE48-D12A-42C1-9487-5C0FD39E0C6E Q35750975-6A47EEDB-FEEA-4F1F-B049-BB739A9EDD04 Q36054919-1949675F-DFB3-45CC-9F71-25708BDB3208 Q36310182-D8C540D5-103C-4B20-B784-140E05A572EA Q36314809-B7E66145-F331-4BB3-A6B3-AB79E78148DC Q36406956-3B763F56-8BA1-425C-A7FF-FB547CB629A9 Q36600567-50D3B0C9-60DF-481A-9847-AE36155E786D Q36973553-4449501D-D9C9-468A-9A20-81FAB18B1699 Q37478633-6BBAE2EE-C4A0-4B5A-BECA-66AAB3D4EDC9 Q37612632-A17CC678-5B0D-4BF8-92BE-7D02205C4115 Q37644499-7DF8867B-6D6F-4E55-92F8-77C05E2DEE5F Q37676257-906FAD11-9171-46AC-8FD2-9C3EC7EDA73A Q37681783-49C85A73-1FC2-46A0-8016-ED7FCD0176D8 Q37682756-AA019935-C876-4FFD-8287-810608D38C25 Q37894668-9D51BE6D-AB98-4AB9-AA25-FF97CA0C0180 Q37933675-CDEDD578-5025-49E2-B525-9B5611A42592 Q37944437-C930E6C6-564A-4233-8E5A-75F91803EFBB Q38062792-BA4D1FD2-6C00-428E-AD4F-D38453A7AA9A Q38255032-8FD30802-96B1-4248-B7B9-45D1ED4C7248 Q38667456-761253F1-92B4-4597-BC83-0A9DEB5CFA4D Q38946859-C2843086-3F11-4FBE-B8E1-A1D3B2F0D894 Q39706095-4135F0EA-35D5-44E0-8AC5-FC4D41E00F0D Q41471527-A9BD93C5-C492-4321-A596-ED4716F9A6C3 Q46298603-20BCC6DF-597D-404B-BA73-3C905B7A96FA Q46552540-8A199B66-2E3D-4A63-899B-CD9C700C96B8 Q47140336-3B8656E4-C2CD-4C67-8FCD-951A40D3D14E Q47406507-51C4C579-F500-4544-986C-6CCBA99F424F Q48076060-D3167EB6-FC17-477C-81DB-F744B4B9E05E

P2860

A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment.

http://www.wikidata.org/entity/Q30421675

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

A 20-gene model for molecular ...... nt and prospective assessment.

@ast

A 20-gene model for molecular ...... nt and prospective assessment.

@en

type

label

A 20-gene model for molecular ...... nt and prospective assessment.

@ast

A 20-gene model for molecular ...... nt and prospective assessment.

@en

prefLabel

A 20-gene model for molecular ...... nt and prospective assessment.

@ast

A 20-gene model for molecular ...... nt and prospective assessment.

@en

P1433

Q30421675-38E7F61B-0EC2-4B01-8A59-8A237E555F26

P1476

Q30421675-7089D536-5541-4851-BE7B-22ACC2E1D75F

P2093

Q30421675-16B476BF-22DD-460F-923C-2C598440F01E

Q30421675-281EE194-26DF-4542-9459-68FE8E153DED

Q30421675-3221B941-C76B-4A2A-BCC5-E4AD4096B1C7

Q30421675-5530130A-FBF5-4CA4-9DA3-0257A6013888

Q30421675-6F2FA3B8-8CCB-4AF6-9AAA-7AD5175C8DFC

Q30421675-77E32BFC-8695-412F-B6EF-A9325991FD0B

Q30421675-8424B0E4-CD02-4F1D-8C48-C74FA5EC468F

Q30421675-89ABBD78-52C4-42C4-9678-E94CA35A8106

Q30421675-B4733751-3C87-483D-9D99-9EB2AD31E2C5

Q30421675-DD9BE9A2-5953-4442-AC75-6A438FC3F920

P2860

Q30421675-2A3E4CF5-7C6B-4612-841B-C60C6AEA35CE

Q30421675-2F98227B-9115-47B8-8D89-592C71D72538

Q30421675-346F457C-7529-4C29-A594-1E839D28479E

Q30421675-38E64A61-4B0F-4AFB-8F21-DC3EFC4D94FC

Q30421675-3A22934F-22BB-4D3A-AF81-446273C92177

Q30421675-3BD8A51C-7FFD-4A03-9579-EC4EA489A676

Q30421675-41D5556C-DFF2-40E7-819B-55519FB37DFB

Q30421675-4597A562-CD11-4822-A0B0-3C33CB33993A

Q30421675-53032B94-0295-4C8A-ACBA-F0F95285B765

Q30421675-614E74B5-2057-4A01-B218-89F5647FE4CD

P304

Q30421675-86F1490D-F317-42D0-B727-267727B93F80

P31

Q30421675-E640ACD2-D1FF-4FF8-A6F9-5DA9B6090C01

P356

Q30421675-221534E8-409D-484F-8E67-052B1E369553

P433

Q30421675-1180EF2F-3CE0-467D-AE6C-1264294F28EE

P478

Q30421675-B3C906DF-0662-4117-A2C1-61048569A9C9

P50

Q30421675-0D698FE8-A114-4A6B-B07A-492D6C4541DD

P577

Q30421675-01B47519-1A4B-4BF1-8696-307AD431138C

P5875

Q30421675-1A3B097D-8B40-4D75-A8C4-E95D1FCACBAD

P698

Q30421675-B13E957F-8B01-4F8E-B3CD-D55915394295

P932

Q30421675-23224F86-3AEA-4B25-97A5-D9DE60BA4001

P356

S1470-2045(10)70296-5

P1433

The Lancet Oncology

P1476

A 20-gene model for molecular ...... nt and prospective assessment.

@en

P2093

Alexander Spyridon Baras

http://www.w3.org/2001/XMLSchema#string

Arndt Hartmann

http://www.w3.org/2001/XMLSchema#string

Dan Theodorescu

http://www.w3.org/2001/XMLSchema#string

Garrett Dancik

http://www.w3.org/2001/XMLSchema#string

Jae K Lee

http://www.w3.org/2001/XMLSchema#string

Jan Lehmann

http://www.w3.org/2001/XMLSchema#string

Kuan-Fu Ding

http://www.w3.org/2001/XMLSchema#string

Michael Stöckle

http://www.w3.org/2001/XMLSchema#string

Steven Christopher Smith

http://www.w3.org/2001/XMLSchema#string

Yuanbin Ru

http://www.w3.org/2001/XMLSchema#string

P2860

Neo-adjuvant chemotherapy for invasive bladder cancer

Summaries of Affymetrix GeneChip probe level data

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

Bladder cancer: narrowing the gap between evidence and practice

The COXEN principle: translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer.

Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy

A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery

Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base.

Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues.

Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer.

P304

137-143

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S1470-2045(10)70296-5

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Christopher Moskaluk

P577

2011-01-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49775415

http://www.w3.org/2001/XMLSchema#string

P698

21256081

http://www.w3.org/2001/XMLSchema#string

P932

3613042

http://www.w3.org/2001/XMLSchema#string